Skip to main content

Table 7 Significant pathways (P < 0.01) by a combined analysis using the Plink set-based test and GSEA.

From: Integrative pathway analysis of genome-wide association studies and gene expression data in prostate cancer

Pathway (KEGG ID) GSEA Plink P combined FDR
Fc gamma R-mediated phagocytosis (hsa04666) < 0.001 0.003 6.18 × 10-8 9.15 × 10-6
Regulation of actin cytoskeleton (hsa04810) 0.009 0.003 3.34 × 10-4 2.47 × 10-2
Jak-STAT signaling pathway (hsa04630) 0.084 0.001 8.79 × 10-4 3.56 × 10-2
Dilated cardiomyopathy (hsa05414) 0.003 0.024 9.63 × 10-4 3.56 × 10-2
Small cell lung cancer (hsa05222) 0.266 0.001 2.45 × 10-3 7.27 × 10-2
Hypertrophic cardiomyopathy (HCM) (hsa05410) 0.009 0.051 4.20 × 10-3 9.62 × 10-2
Cell cycle (hsa04110) 0.251 0.003 6.16 × 10-3 9.62 × 10-2
Arrhythmogenic right ventricular cardiomyopathy (ARVC) (hsa05412) 0.012 0.068 6.46 × 10-3 9.62 × 10-2
Chronic myeloid leukemia (hsa05220) 0.843 0.001 6.80 × 10-3 9.62 × 10-2
Bladder cancer (hsa05219) 0.422 0.002 6.80 × 10-3 9.62 × 10-2
Wnt signaling pathway (hsa04310) 0.297 0.003 7.14 × 10-3 9.62 × 10-2
TGF-beta signaling pathway (hsa04350) 0.508 0.002 8.01 × 10-3 9.66 × 10-2
Axon guidance (hsa04360) 0.016 0.074 9.18 × 10-3 9.66 × 10-2